Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Total Liabilities & Equity

Total Liabilities & Equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.99B+0.3%
Biogen logo
BiogenBIIB
$32.09B+13.3%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$1.74B+42.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%
uniQure logo
uniQureQURE
$985.1M+68.4%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$230.44M-3.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$47.3M-77.0%
Net income-$46.6M-73.5%
EPS (diluted)-$0.13-44.4%

Balance sheet

See full
Cash & equivalents$455.4M+45.6%
Total debt$56.7M-5.1%
Total equity$387.3M+55.7%
Total assets$470.4M+41.1%

Cash flow

See full
Operating cash flow-$40.4M-100%
CapEx$24.0K-93.7%
Free cash flow-$40.4M-100%

Valuation

See full
Market cap$1.83B+154%
Enterprise value$1.43B+205%
P/S333.7×+245×

Profitability

See full
Operating margin-2,792.3%-9,679pp
Net margin-2,728%-9,858pp
FCF margin-2,417%-8,925pp

Returns & leverage

See full
Return on equity-47.1%-4.0pp
Debt / equity0.1×-0.1×
Current ratio17.8×+5.3×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344610
Line itemJune 30,2026December 31,2025
Stockholders' equity
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 325,302,280 and 285,051,648 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively33
Additional paid-in capital1,186,843958,427
Accumulated other comprehensive income (loss)769(192)
Accumulated deficit(800,349)(711,300)
Total stockholders’ equity387,266246,938
Total liabilities and stockholders' equity$470,433$343,320

Item 1. Financial Statements.

FAQ

What is Taysha Gene Therapies, Inc.'s total liabilities & equity?
Taysha Gene Therapies, Inc. (TSHA) reported total liabilities & equity of $470.43M in Q2 2026.
How has Taysha Gene Therapies, Inc.'s total liabilities & equity changed year-over-year?
Taysha Gene Therapies, Inc.'s total liabilities & equity increased by 41.1% year-over-year, from $333.33M to $470.43M.
What is the long-term trend for Taysha Gene Therapies, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s total liabilities & equity has grown at a 5.8% compound annual growth rate (CAGR), from $258.88M to $343.32M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Taysha Gene Therapies, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude